Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (July 2026)
13 slides from Island Pharmaceuticals's investor presentation, Jul 8, 2026
Slide 1: Combatting Urgent Viral Disease Threats
COMBATTING URGENT VIRAL DISEASE THREATS Advancing Galidesivir as a multi-filovirus countermeasure Dr. David Foster – Managing Director & CEO – Mr. Jason Carroll - Non-Executive Chairman July 2026 ASX: ILA
Slide 2: Company Overview
Company Overview Shares on issue¹: 295,916,682 Price per share¹: $0.475 Substantial shareholders Market capitalisation¹: $140.6m Dr William James Garner³ 15.50% Cash at bank (31 March 2026)²: $14.2m Jason Alan Carroll³ 11.92% Potential additional capital from vested options where ~$1.6m MWP Partners
Slide 3: Current Ebola & Marburg Outbreak
Current Ebola & Marburg Outbreak An urgent and growing global security challenge Extremely high fatality rates: Marburg up to 88%, Ebola up to 90%, Sudan up to 47%, Bundibugyo 30–50% Limited countermeasures: BSL-4 pathogens: Bioterror relevance: Current situation: No approved Require maximum Histori
Slide 4: African regions affected by the Ebola outbreak
African regions affected by the Ebola outbreak • May 2026: Bundibugyo Ebola outbreak declared in the DRC and Uganda. • 1,582 confirmed cases and 508 deaths (July 4, 2026). • Third-largest Ebola outbreak on record. • WHO: Public Health Emergency of International Concern. • CDC: Public health emergenc
Slide 5: Increase in Ebola cases in 2026
Increase in Ebola cases in 2026 This Outbreak Is Different From Any Before John Drake, leading ecologist and infectious disease professor, 24 June 2026 Source: https://www.forbes.com/sites/johndrake/2026/06/24/ebola-has-passed-1000-cases-this-outbreak-is-different-from-any-before/ Island Pharmaceuti
Slide 6: Why Galidesivir?
Why Galidesivir? A broad-acting small molecule antiviral with strong filovirus efficacy and FDA-aligned pathway IV and IM formulations with favorable Demonstrated multi-filovirus activity safety profile- the ideal product profile (Marburg, Ebola, Sudan) for Africa Manufacturing route improved with 2
Slide 7: Government-Approved Africa Protocol
Government-Approved Africa Protocol Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework Government approvals have been secured to evaluate Galidesivir during the active Bundibugyo Ebola outbreak in Uganda under the WHO MEURI framework, creating a unique opport
Slide 8: Dual Development Strategy
Dual Development Strategy Two complementary pathways advancing Galidesivir towards regulatory approval Pathway 1 Pathway 2 Human Ebola Study FDA Animal Rule Program WHO MEURI Framework USAMRIID Marburg challenge study Real-world clinical data Controlled non-human primate efficacy data Bundibugyo Ebo
Slide 9: Marburg NHP Survival
MARBURG NHP SURVIVAL 94% survival in Marburg NHP Model with treatment initiated up to 48 hours post-infection This level of efficacy, with a clinically meaningful therapeutic window, is rare in filovirus models and directly supports Animal Rule advancement Island Pharmaceuticals Limited 09
Slide 10: Ebola NHP Survival
EBOLA NHP SURVIVAL Robust efficacy in Ebola NHP model with delayed dosing Survival of rhesus non-human primates challenged with Ebola virus following intramuscular administration of 100 mg/kg BID loading dose followed by 25 mg/kg BID for 10 days. 100% survival when treatment commenced 2 days post Pe
Slide 11: Regulatory & Commercial Opportunity
Regulatory & Commercial Opportunity A clear pathway to regulatory approval and commercialisation Regulatory pathway Priority Review Voucher Government Procurement Strategic National for Galidesivir (PRV) Stockpile Potential FDA Animal Rule Potential PRV procurement by Potential supported by
Slide 12: Near-Term Catalysts
Near-Term Catalysts A number of value catalysts pending in the coming months Milestone Timeframe Establish Fellows Program to provide expert access to strategic subject matter KOLs Complete FDA feedback on Galidesivir protocol clarifying questions Received Government-approved deployment of Galidesiv
Slide 13: Island Pharmaceuticals
Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — Investor Presentation (July 2026) on 6ix